A new treatment option, Datroway (datopotamab deruxtecan or Dato-DXd), is now available for people with non-small cell lung ...

Datroway is used to treat an advanced form of non-small cell lung cancer in adults who had received prior treatment.

Datroway (datopotamab deruxtecan) is the first TROP2-directed therapy approved for advanced lung cancer in the U.S.

The FDA has approved AstraZeneca and Daiichi Sankyo's Datroway (Datopotamab deruxtecan) for adults with NSCLC.

AstraZeneca PLC (NASDAQ:AZN) is one of the 12 stocks that will make you rich in 10 years. On June 23, the company announced ...

The FDA has blessed AstraZeneca and Daiichi Sankyo’s Datroway to treat patients with locally advanced or metastatic epidermal ...

The drug was approved to treat patients who have already received chemotherapy under an accelerated approval process after a ...

Breaking down what patients should know about each FDA therapeutic approval from June 2025 across various oncology ...

Datroway received accelerated FDA approval for adults with EGFR+ advanced non-small cell lung cancer after EGFR-targeted and ...

The US Food and Drug Administration (FDA) has approved Datroway (datopotamab deruxtecan or Dato-DXd) to treat adults with ...

DATROWAY ® has been approved in the US for the treatment of adult patients with locally advanced or metastatic EGFR- mutated non-small cell lung cancer who have received prior EGFR- directed ...